The GW9662 treatment dramatically decreased the mRNA level of DCX (Fig. 3B), and reduced the proliferation and differentiation of NPCs when compared with that of GRb1 administration in the CMS group (Fig. 3C–E). Here, PIK3R1 is linked to congenital myasthenic syndrome.